Forus Lands $150M to Scale Medicine Network

The big picture: Forus, the AI network accelerating medicine, announced $150 million in Series C financing at a $3 billion valuation, tripling its valuation just months after its Series B. The round brings total funding to more than $300 million. The company’s platform is now used by providers across all 50 states to treat patients in 85% of U.S. residential ZIP codes. Learn more at forus.com.

Why it matters:

• Patient Access Gap: One in three people prescribed high-cost or complex medication never get their first dose, often waiting weeks or months for treatment to begin.
• Physician Confidence: Physicians often prescribe older medicines due to uncertainty and process complexity with new therapies, leading to less effective treatment than the latest science allows.
• Biopharma Impact: Bringing a single new medicine to market takes over a decade and billions of dollars, yet that science reaches only a fraction of the people who need it.

How it works:

• AI Agent Automation: Forus embeds AI agents directly into provider workflows, managing everything between a clinical decision and a patient starting treatment, including insurance, financial assistance, and supply chain.
• Personalized Navigation: Each agent acts as a case manager, reasoning through the patient’s medical history, insurance coverage, and financial situation to determine the next steps.
• Predictable Treatment: The platform simplifies and accelerates patient access to necessary medications, providing predictability for clinical teams and enabling confident prescribing of the most effective treatment from day one.

The catch: The market for healthcare AI is highly competitive, and scaling across all specialties and care settings presents significant integration and regulatory challenges. Ensuring data privacy and security across a vast network of providers, payers, and biopharma companies is paramount. The reliance on AI agents for critical patient pathways also introduces a need for robust oversight and explainability to maintain trust and clinical efficacy.